Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HINT1 | P49773 | 5/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 6/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22292279 | 1.00 | NT5E (0.55) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL15280835 | 0.93 | NT5E (0.57) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL22292281 | 0.93 | NT5E (0.57) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL15280827 | 0.91 | NT5E (0.48) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL19522904 | 0.91 | NT5E (0.56) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL19887029 | 0.91 | NT5E (0.48) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL22060522 | 0.91 | NT5E (0.48) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL19887068 | 0.88 | NT5E (0.48) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL15280802 | 0.88 | NT5E (0.48) | NT5EHINT1FUT5TGM2KRAS | |
| SCHEMBL22292278 | 0.87 | HINT1 (0.58) | NT5EHINT1FUT5TGM2KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | NT5E 963/4885HINT1 2496/4885FUT5 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.